drugset / Trial / NCT02182713

Combivent vs. Salbutamol in Patients With Metacholine Induced Bronchospasm

NCT02182713

Phase 4 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverDouble-blindTreatment

Summary

The purpose of this study was to evaluate whether 2 puffs of fixed combination of aerosolized 120 mcg salbutamol sulphate (equivalent to 100 mcg of the base) + 20 mcg ipratropium bromide confers significant additional protection against metacholine induced bronchoconstriction in asthmatic atopic patients when compared to 2 puffs of aerosolized 100 mcg salbutamol alone.

Timeline

Start
1998-05
Primary completion
1998-09
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Ipratropium Small molecule 20 ug
Subject Salbutamol Unknown 100 ug Inhaled
Subject Salbutamol Unknown 120 ug Inhaled

Indications